{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:20:39Z","timestamp":1778037639927,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guidelines in effect from 2018, the design of Asia\u2010inclusive multiregional clinical trials (MRCTs) has been streamlined, thereby enabling efficient simultaneous global development. Furthermore, with the recent regulatory reforms in China and its drug administration joining the ICH as a full regulatory member, early participation of China in the global clinical development of novel investigational drugs is now feasible. This would also allow for inclusion of the region in the geographic footprint of pivotal MRCTs leveraging principles of the ICH E5 and E17. Herein, we describe recent case examples of model\u2010informed Asia\u2010inclusive global clinical development in the EMD Serono portfolio, as applied to the ataxia telangiectasia and Rad3\u2010related inhibitors, tuvusertib and berzosertib (oncology), the toll\u2010like receptor 7\/8 antagonist, enpatoran (autoimmune diseases), the mesenchymal\u2013epithelial transition factor inhibitor tepotinib (oncology), and the antimetabolite cladribine (neuroimmunological disease). Through these case studies, we illustrate pragmatic approaches to ethnic sensitivity assessments and the application of a model\u2010informed drug development toolkit including population pharmacokinetic\/pharmacodynamic modeling and pharmacometric disease progression modeling and simulation to enable early conduct of Asia\u2010inclusive MRCTs. These examples demonstrate the value of a <jats:italic>Totality of Evidence<\/jats:italic> approach where every patient's data matter for de\u2010risking ethnic sensitivity to inter\u2010population variations in drug\u2010 and disease\u2010related intrinsic and extrinsic factors, enabling inclusive global development strategies and timely evidence generation for characterizing benefit\/risk of the proposed dosage in Asian populations.<\/jats:p>","DOI":"10.1111\/cts.70050","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T11:06:02Z","timestamp":1729767962000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Asia\u2010inclusive drug development leveraging principles of <scp>ICH E5<\/scp> and <scp>E17<\/scp> guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5593-6533","authenticated-orcid":false,"given":"Hong","family":"Lu","sequence":"first","affiliation":[{"name":"Merck Serono (Beijing) Pharmaceutical R&amp;D Co., Ltd.  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-3416","authenticated-orcid":false,"given":"Lena","family":"Klopp\u2010Schulze","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7969-9238","authenticated-orcid":false,"given":"Jatinder Kaur","family":"Mukker","sequence":"additional","affiliation":[{"name":"EMD Serono Research and Development Institute Inc.  Billerica Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4734-7365","authenticated-orcid":false,"given":"Dandan","family":"Li","sequence":"additional","affiliation":[{"name":"Merck Serono (Beijing) Pharmaceutical R&amp;D Co., Ltd.  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3400-8983","authenticated-orcid":false,"given":"Yoshihiro","family":"Kuroki","sequence":"additional","affiliation":[{"name":"Japan Merck Biopharma Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-7819","authenticated-orcid":false,"given":"Jayaprakasam","family":"Bolleddula","sequence":"additional","affiliation":[{"name":"EMD Serono Research and Development Institute Inc.  Billerica Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-3695","authenticated-orcid":false,"given":"Nadia","family":"Terranova","sequence":"additional","affiliation":[{"name":"Ares Trading S.A. (an Affiliate of Merck KGaA, Darmstadt, Germany)  Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-8283","authenticated-orcid":false,"given":"Kosalaram","family":"Goteti","sequence":"additional","affiliation":[{"name":"EMD Serono Research and Development Institute Inc.  Billerica Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3149-8486","authenticated-orcid":false,"given":"Wei","family":"Gao","sequence":"additional","affiliation":[{"name":"EMD Serono Research and Development Institute Inc.  Billerica Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-7984","authenticated-orcid":false,"given":"Rainer","family":"Strotmann","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA  Darmstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-7074","authenticated-orcid":false,"given":"Jennifer","family":"Dong","sequence":"additional","affiliation":[{"name":"EMD Serono Research and Development Institute Inc.  Billerica Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-9813","authenticated-orcid":false,"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"EMD Serono Research and Development Institute Inc.  Billerica Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.Ethnic Factors in the Acceptability of Foreign Clinical Data E5(R1). ICH website.https:\/\/database.ich.org\/sites\/default\/files\/E5_R1__Guideline.pdf. Accessed February 9 2023."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774518813573"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479018764661"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2591"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2409"},{"key":"e_1_2_9_8_1","unstructured":"Testing the combination of two anticancer drugs M1774 (tuvusertib) and avelumab to evaluate their safety and effectiveness in treating Merkel cell skin cancer MATRiX trial. ClinicalTrials website.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05947500. Accessed February 9 2023."},{"key":"e_1_2_9_9_1","unstructured":"Clinical pharmacology and biopharmaceutics review(s).Application number: 206545Orig1s000. Center for Drug Evaluation and Research. US FDA website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206545Orig1s000ClinPharmR.pdf\u2009206545Orig1s000ClinPharmR.pdf(fda.gov). Accessed February 9 2023."},{"key":"e_1_2_9_10_1","unstructured":"US Food and Drug Administration.Pfizer Inc. GEODON\u00ae (Ziprasidone): Summary of Product Characteristics. US FDA website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020825s035 020919s023lbl.pdf. Accessed February 9 2023."},{"key":"e_1_2_9_11_1","unstructured":"US Food and Drug Admisnitration.Novartis. TABRECTA\u2122 (Capmatinib): Highlights of Prescribing information. US FDA website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf. Accessed February 9 2023."},{"key":"e_1_2_9_12_1","unstructured":"The WILLOW study with M5049 in SLE and CLE (SCLE and\/or DLE) (WILLOW). ClinicalTrials website.https:\/\/clinicaltrials.gov\/study\/NCT05162586. Accessed February 9 2023."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.842"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13658"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2606"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3216"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12888"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04184-z"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0536"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217313"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01405-x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6915"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.02.014"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1629"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004407"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01317-9"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04423-5"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01422-9"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13166"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:34:46Z","timestamp":1729863286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/cts.70050"],"URL":"https:\/\/doi.org\/10.1111\/cts.70050","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70050"}}